Exagen Inc. (NASDAQ:XGN - Free Report) - Investment analysts at KeyCorp issued their FY2026 earnings per share estimates for Exagen in a research note issued to investors on Tuesday, November 10th. KeyCorp analyst P. Knight anticipates that the company will earn ($0.71) per share for the year. The consensus estimate for Exagen's current full-year earnings is ($0.71) per share. KeyCorp also issued estimates for Exagen's Q4 2026 earnings at ($0.16) EPS and FY2027 earnings at ($0.49) EPS.
A number of other research analysts have also commented on the company. TD Cowen upped their price target on Exagen from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, October 13th. Wall Street Zen lowered Exagen from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Exagen in a research report on Wednesday, November 4th. BTIG Research reissued a "buy" rating and set a $9.00 target price on shares of Exagen in a research note on Wednesday, November 11th. Finally, B. Riley Financial initiated coverage on Exagen in a report on Friday, September 11th. They set a "buy" rating and a $12.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $9.88.
Check Out Our Latest Stock Report on Exagen
Exagen Stock Performance
Exagen stock opened at $4.13 on Monday. The company has a current ratio of 3.46, a quick ratio of 3.46 and a debt-to-equity ratio of 1.73. The firm has a market cap of $105.36 million, a P/E ratio of -5.51 and a beta of 2.25. Exagen has a 1-year low of $2.59 and a 1-year high of $9.28. The firm has a 50-day moving average of $7.71 and a 200-day moving average of $5.13.
Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $18.42 million for the quarter, compared to analysts' expectations of $18.34 million. Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%.
Hedge Funds Weigh In On Exagen
A number of hedge funds have recently bought and sold shares of the company. Flputnam Investment Management Co. bought a new position in shares of Exagen in the second quarter worth approximately $1,343,000. GSA Capital Partners LLP purchased a new stake in shares of Exagen during the second quarter valued at approximately $998,000. Man Group plc bought a new stake in shares of Exagen during the second quarter valued at approximately $778,000. FourWorld Capital Management LLC increased its position in shares of Exagen by 61.2% during the first quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company's stock valued at $1,320,000 after acquiring an additional 166,950 shares in the last quarter. Finally, BlackRock Inc. bought a new stake in shares of Exagen during the second quarter valued at approximately $663,000. Institutional investors own 75.25% of the company's stock.
Insider Activity
In other Exagen news, CEO John Aballi sold 34,294 shares of the firm's stock in a transaction on Friday, October 16th. The stock was sold at an average price of $7.87, for a total transaction of $269,893.78. Following the completion of the transaction, the chief executive officer owned 805,540 shares of the company's stock, valued at approximately $6,339,599.80. This trade represents a 4.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Jorey Chernett sold 58,068 shares of the business's stock in a transaction on Friday, November 13th. The shares were sold at an average price of $4.08, for a total transaction of $236,917.44. Following the sale, the insider owned 2,529,436 shares in the company, valued at approximately $10,320,098.88. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders acquired 100,900 shares of company stock valued at $568,660 and sold 213,063 shares valued at $1,084,856. Company insiders own 10.40% of the company's stock.
Key Exagen News
Investors following XGN have been watching these news items:
- Neutral Sentiment: Major shareholder Jorey Chernett recently made purchases as well as sales. KeyCorp’s 2026 loss estimate matches consensus, offering little change to current expectations.
- Negative Sentiment: Chernett sold 167,504 shares on Nov. 12–13 for about $746,000, a notable signal of insider selling despite his recent purchases. Article: Exagen Major Shareholder Sells Stock
- Negative Sentiment: Exagen’s latest quarterly loss per share was wider than analysts expected, even though revenue slightly beat estimates. Wall Street Zen downgraded the stock to Sell, while Canaccord lowered its price target from $11 to $9 but maintained a Buy rating. Article: Exagen Stock Rating Cut to Sell Article: Exagen Stock Gets Price Target Trim
Exagen Company Profile
(
Get Free Report)
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company's AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.